Table 3. Correlation between percentage of patients treated with both PBC and EGFR-TKIs during the course of the disease and the reported OS.

First author/year	No. of Pts (%)		Response rate (%)	Reported OS (months)	Asian (%)	Caucasian (%)	Adenocarcinoma (%)	Squamous (%)
Mok TS/2010 [23]	609	(64.5)	43.0	18.8	99.7	NR	95.4	0
	608	(51.5)	32.2	17.3	99.8	NR	97.2	0
Okamoto I/2010 [31]	281	(24.0)	29.0	13.3	100	0	69.4	30.6
	282	(27.2)	20.4	15.2	100	0	69.1	30.9
Kubota K/2008 [32]	196	NA	25.0	13.6	100	0	66	23
	197	(40.0)	37.0	14.1	100	0	76	15
Ohe Y/2007 [33]	145	(7.6)	31.0	13.9	100	0	83.4	11
	145	(6.2)	32.4	12.3	100	0	71.7	21.4
	146	(12.3)	30.1	14	100	0	74	19.9
	145	(8.3)	33.1	11.4	100	0	75.2	20
Kubota K/2004 [34]	151	(3.0)	25	11.3	100	0	79.5	11.3
	151	(1.0)	37	9.6	100	0	68.2	21.9
Han JY/2012 [24]	159	(65.0)	55.4	22.3	100	0	100	0
	150	(75.0)	46.0	22.9	100	0	100	0
Lara PN Jr/2011 [35]	649	(20.5)	24.7	13.4	25	71.5	66.5	20.3
	650	(21.4)	24.6	12.7	25.2	71.5	67.1	20.5
Reck M/2010 [36]	347	(25.0)	21.6	13.1	8	92	82	NR
	345	(29.0)	37.8	13.6	9	91	85	NR
	351	(24.0)	34.6	13.4	9	91	85	NR
Lynch TJ/2010 [37]	338	(25.1)	25.7	9.69	2	88	51	20
	338	(22.8)	17.2	8.38	3	89	54	19
Pirker R/2009 [38]	557	(17.0)	36.0	11.3	11	84	46	34
	568	(27.0)	29.0	10.1	10	85	49	33
Tan EH/2009 [39]	194	(15.5)	31.2	9.9	0	100	41.6	34.2
	196	(15.8)	29.6	9.8	0	100	39.3	33.5
Scagliotti GV/2008 [8]	830	(22.5)	28.2	10.3	12.1	78.8	47.6	26.5
	839	(24.9)	30.6	10.3	13.5	77.6	50.6	28.3
Ramlau R/2008 [40]	311	(11.0)	16.7	8.7	1	89	39	38
	312	(13.0)	24.4	9.9	1	92	41	36
Blumenschein GR Jr /2008 [41]	306	(22.0)	19.3	8.5	NR	88	55	20
	306	(27.0)	23.5	9.2	NR	89	50	21
Sandler A/2011 [42]	417	(13.7)	35.0	12.3	25.0	91.0	88.0	20.3
	433	(17.8)	15.0	10.3	25.2	90.0	88.0	20.5

Pts, patients; PS, performance status; OS, overall survival; NA, not available. NR, not reported.